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Thirteen patients with pachyonychia congenita types
1 and 2 were studied, two of which had a family his-
tory of pachyonychia and 11 of which were sporadic
cases. Heterozygous mis-sense or small in-frame
insertion/deletion mutations were detected in the
genes encoding keratins K6a, K16, and K17 in all
cases. Three novel mutations, F174V, E472K, and
L469R were found in the K6a gene. Two novel
mutations, M121T and L128Q were detected in K16.
Similarly, three novel mutations, L95P, S97del, and
L99P were found in K17. In addition, we identi®ed
recurrent mutations N171del (three instances) and
F174S in K6a and R94H in K17. Analysis of both
phenotype and genotype data led to the following
conclusions: (i) K6a or K16 mutations produce the
pachyonychia congenita type 1 phenotype, whereas
K17 (or K6b) mutations cause pachyonychia con-
genita type 2; (ii) the presence of pilosebaceous cysts
following puberty is the best indicator of pachyony-
chia congenita type 2; (iii) prepubescent patients are
more dif®cult to classify due to the lack of cysts; and
(iv) natal teeth are indicative of pachyonychia con-
genita type 2, although their absence does not pre-
clude the pachyonychia congenita type 2 phenotype.
This study establishes useful diagnostic criteria for
pachyonychia congenita types 1 and 2, which will
help limit unnecessary DNA analysis in the diagnosis
and management of this genetically heterogeneous
group of genodermatoses. Key words: genodermatoses/
keratin/mutation/nail dystrophy/pachyonychia congenita. J
Invest Dermatol 117:1391±1396, 2001
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eratin intermediate ®laments are the main stress-
bearing cytoskeletal system within the cytoplasm of
epithelial cells (Corden and McLean, 2001). Keratins
form heteropolymers consisting of speci®c pairs of
type I and type II proteins that are expressed in a
tissue-speci®c and differentiation-speci®c fashion (Lane, 1993).
Their assembly into 10 nm intermediate ®laments is mediated by
their central coiled-coil a-helical rod domains (Quinlan et al,
1994). Conserved sequences at both ends of the rod domain,
termed the helix boundary motifs, are known to be involved in
end-to-end interactions in ®lament assembly (Steinert et al, 1993;
Herrmann et al, 2000). In recent years, genetic mutations affecting
the assembly and/or integrity of keratin intermediate ®laments have
been shown to be the cause of a wide variety of human genetic
disorders of keratinization (Fuchs and Cleveland, 1998; Irvine and
McLean, 1999). The majority of keratin mutations are dominant
acting and mostly involve mis-sense or small in-frame insertion/
deletion mutations clustering at the ends of the rod domain of the
keratin molecule (Corden and McLean, 1996).
Pachyonychia congenita (PC) is an autosomal dominant group of
ectodermal dysplasias characterized by hypertrophic nail dystrophy,
hyponychial keratosis, palmoplantar keratoderma, and other
ectodermal changes (Jadassohn and Lewandowsky, 1906; Jackson
and Lawler, 1951). Two clinical subtypes of PC have been
described: the Jadassohn±Lewandowsky or PC-1 type (OMIM no.
167200) and the Jackson±Lawler or PC-2 variant (OMIM no.
167210). In PC-1, oral leukokeratosis, palmoplantar keratoderma,
and follicular keratosis may be observed (Jadassohn and
Lewandowsky, 1906). The PC-2 subtype is characterized by the
presence of additional features, including multiple pilosebaceous
cysts, neonatal teeth, and pili torti (Jackson and Lawler, 1951). In
PC-2, oral leukokeratosis can occur (Smith et al, 1998) but appears
to be less frequently observed than in PC-1. In our experience, the
presence of widespread pilosebaceous cysts following puberty is the
best distinguishing feature of PC-2. Histologically, these cysts are
heterogeneous: some the result of infundibular hyperkeratosis and
others are steatocysts (Munro et al, 1994).
PC-1 has been shown to be caused by mutations in the genes
encoding keratins K16 (McLean et al, 1995) and K6a (Bowden et al,
1995). These keratins are coexpressed in the epithelial tissues
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affected in PC-1 (Weiss et al, 1984). In contrast, PC-2 has been
shown to result from mutations in the K17 gene (McLean et al,
1995), a keratin expressed in the tissues affected in PC-2
(Troyanovsky et al, 1989; McGowan and Coulombe, 1998).
Recently, a mutation in the K6b gene was reported in an extensive
family presenting with the PC-2 phenotype (Smith et al, 1998).
This mutation, together with coexpression data demonstrated that
K6b is the expression partner of K17 in the tissues affected in PC-2
(Smith et al, 1998).
Here, we have analyzed 13 kindreds with PC and have found
eight novel and ®ve recurrent keratin mutations.
MATERIALS AND METHODS
Sample collection Genomic DNA samples were extracted from
peripheral blood lymphocytes of the patients by standard methods.
Mutation detection and con®rmation PCR primers and programs
used for speci®c ampli®cation of the mutation hotspot regions of the
genes encoding K6a and K16 without coampli®cation of homologous
pseudogenes and/or isogenes, were described previously (Smith et al,
1999a, b). Exon 1 of the K17 gene was speci®cally ampli®ed as reported
previously (Covello et al, 1998). The full-length functional K17 gene
(KRT17A) was speci®cally ampli®ed using primers K17P8 and K17P13
(Table I) using standard PCR buffer containing 1.5 mM MgCl2 (Perkin-
Elmer, Foster City, CA) and 4% dimethyl sulfoxide. This reaction was
subjected to a ``hot start'' with 1 U of Long Range PCR enzyme mix
(Boehringer, Mannheim, Germany) and the following PCR conditions
were used: (94°C 5 min) 3 1; (94°C 30 s, 58.5°C 1 min, 72°C
2.5 min) 3 34; (72°C 5 min) 3 1. Mutation detection was performed
by direct sequencing of PCR products using the ampli®cation
oligonucleotides or additional internal primers. Sequences were
compared with that of an unaffected, unrelated control sample. Sequence
analysis was performed using Big Dye terminator chemistry on an ABI
377 genetic analyzer (Perkin-Elmer).
For the novel mutations, we performed a series of restriction enzyme
digestions of short PCR fragments carrying the mutations and of 50
normal unrelated controls to exclude these sequence changes as
polymorphisms in the normal population. In the case of K16, a short
PCR fragment speci®c for exon 1 of the functional KRT16A gene was
used. In the case of K6a and K17 genes, nested PCR was used to
circumvent pseudogene and/or isogene interference with speci®c PCR
fragments generated as above. Short fragments appropriate for digestion
were produced by reampli®cation of a 1:1000 dilution of the full-length
PCR products. For con®rmation of K6a mutation F174V and K17
mutation S97del, mismatch primers were used to create new restriction
sites dependent on the presence of the mutation. In all other cases,
naturally occurring sites were exploited. The PCR reactions and enzymes
used in this analysis, together with the fragment sizes generated from
digestion of normal and mutant alleles are outlined in Table II. The
PCR primers used in this analysis and their optimized annealing
temperatures are listed in Table II. Primer sequences are listed in
Table I.
RESULTS
Case reports In this study we have collected 13 patients,
clinically heterogeneous, diagnosed as PC-1 (Table III, patients 1±
9) and PC-2 (Table III, patients 10±13). In two cases (patients 6
and 12), there was a clear family history of pachyonychia with
typical features of autosomal dominant inheritance. All other
patients were sporadic cases of pachyonychia. Using the presence or
absence of pilosebaceous cysts as the key diagnostic feature, we
initially classi®ed the 13 patients into the PC-1 and PC-2
categories, as shown in Table III. It should be noted that these
cysts only appear at puberty and so younger patients are more
dif®cult to classify. As can be seen from Table III, other features
often used to distinguish the two groups, such as oral leukokeratosis
in PC-1 or natal teeth in PC-2, are not fully expressed and
therefore are less reliable as diagnostic indicators. The presence of
natal teeth, however, is a useful indicator of PC-2 in prepubescent
patients, although the absence of natal teeth does not preclude a
diagnosis of PC-2. It should be noted that in some cases of PC-1,
follicular hyperkeratosis can occur, such as in patient 7 here
(Table III). These lesions may be mistaken for pilosebaceous cysts
and therefore lead to misdiagnosis as PC-2.
The severity of palmoplantar keratoderma varied widely within
both PC types. Most were mildly affected with keratoderma
con®ned only to the pressure areas of plantar epidermis with little
or no palmar involvement. Some cases, however, notably patient 3,
had severe diffuse keratoderma of both palms and soles, resembling
epidermolytic palmoplantar keratoderma. One case (patient 6),
suffered hyperkeratotic lesions of the conjunctiva, when this tissue
was stressed by use of contact lenses. This feature has not previously
been reported in pachyonychia.
Novel and recurrent mutations in PC Patients were screened
for mutations in the K6a, K16, and K17 genes, which have been
previously associated with the PC-1 and PC-2 types of the disease
(Bowden et al, 1995; McLean et al, 1995; Smith et al, 1998). In the
patients diagnosed as PC-1, the entire coding regions of the K6a
and K16 genes were ampli®ed by the long-range PCR protocols
described previously (Smith et al, 1999a, b). K6a mutations were
detected in seven of the PC-1 individuals examined (patients 1±7;
Table I. Primers used for mutation detection/
con®rmation











aMismatch bases used to create new enzyme sites are underlined.
Table II. PCR reactions used for restriction enzyme analysis
Mutation (protein; DNA) Primers, F & R Annealing PCR type PCR size Enzyme Normal bands Mutant bands
K6a F174V; 520T > G K6ap4, K6aHincII 59°C Nested 152 bp HincIIa (+) 130, 22 bp 102, 28, 22 bp
K6a L469R; 1406T > G K6ap8, K6ap9 58°C Nested 379 bp BpmI (±) 205, 117, 57 bp 322, 57 bp
K6a E472K; 1414G > A K6ap8, K6ap9 58°C Nested 379 bp BseRI (±) 202, 177 bp 379 bp
K16 M121T; 362T > C K16sp2, K16sp6 57.5°C Direct 506 bp NlaIII (±) 320, 186 bp 506 bp
K16 L128Q; 383T > A K16sp2, K16sp6 57.5°C Direct 506 bp StuI (+) 506 bp 342, 164 bp
K17 L95P; 284T > C K17P8, K17P4 58°C Nested 437 bp NciI (+) 437, 25 bp 359, 78, 25 bp
K17 S97del; 289delCCT K17P8, K17S®I, 58.5°C Nested 427 bp S®Ia (+) 428 bp 393, 32 bp
K17 L99P; 296T > C K17P8, K17P4 57°C Nested 437 bp NciI (+) 437, 25 bp 371, 66, 25 bp
aNew restriction site created by primer mismatch.
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Table III. Phenotype and genotype data for pachyonychia patients studied
Patient PC type Inheritance PC PPK Orala Ocularb FHc Cystsd NTe Mutationf
1 PC-1 Sporadic + ± ± ± ± ± ± K6a F174V(1A domain F10V)
2 PC-1 Sporadic + + + ± ± ± ± K6a E472K (2B domain E117K)
3 PC-1 Sporadic + + + ± ± ± ± K6a L469R (2B domain L114R)
4 PC-1 Sporadic + ± ± ± ± ± ± K6a N171del (1A domain N8del)
5 PC-1 Sporadic + ± + ± ± ± ± K6a F174S(1A domain F10S)
6 PC-1 Familial + + + + ± ± ± K6a N171del (1A domain N8del)
7 PC-1 Sporadic + + + ± + ± ± K6a N171del (1A domain N8del)
8 PC-1 Sporadic + + + ± ± ± ± K16M121T (1A domain M4T)
9 PC-1 Sporadic + + + ± ± ± ± K16L128Q (1A domain L11Q)
10 PC-2 Sporadic + + ± ± ± + ± K17L95P (1A domain L11P)
11 PC-2 Sporadic + + ± ± ± + ± K17S97del (1A domain S13del)
12 PC-2 Familial + + ± ± ± + + K17L99P (1A domain L15P)
13 PC-2 Sporadic + + ± ± ± + ± K17: R94H (1A domain R10H)
aOral leukokeratosis.
bKeratosis of the ocular mucosa.
cFollicular hyperkeratosis.
dPilosebaceous cysts i.e. steatocysts and/or eruptive vellus hair cysts.
eNatal teeth.
fNumbers in parenthesis refer to the 1A or 2B domain residue numbering system. Novel mutations indicated in bold type, previously reported mutations in plain text.
PPK, palmoplantar keratoderma.
Figure 1 Novel mutations in the K6a gene.
(a) Normal DNA sequence of K6a exon 1, region
encoding the helix initiation motif. (b) DNA
sequence as shown in (a), derived from patient 1,
showing heterozygous mis-sense mutation
520T > G, predicting the amino acid change
F174V (or F10V in the 1 A domain). (c) Normal
DNA sequence of K6a exon 7, region encoding
the helix termination motif. (d) DNA sequence as
shown in (c), derived from patient 2, showing
heterozygous mis-sense mutation 1406T > G,
predicting the amino acid change L469R (or
L114R in the 2B domain). (e) DNA sequence as
shown in (c), derived from patient 3, showing
heterozygous mis-sense mutation 1414G > A,
predicting the amino acid change E472K (or
E117K in the 2B domain). ( f ) Con®rmation of
mutation F174V by HincII digestion.
M, molecular weight markers. Lane 1, digest
derived from patient 1 showing digested mutant
bands; lanes 2±8, digests derived from normal
unrelated controls. (g) Con®rmation of mutation
L469R by BpmI digestion. M, molecular weight
markers. Lane 1, digest derived from patient 2
showing undigested mutant band; lanes 2±
8, digests derived from normal unrelated controls.
(h) Con®rmation of mutation E472K by BseRI
digestion. M, molecular weight markers. Lanes 1,
3±8, digests derived from normal unrelated
controls; lane 2, digest derived from patient 3
showing undigested mutant band.
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Table III). Three of these were novel mutations: F174V, L469R,
and E472K detected in patients 1±3, respectively (Fig 1a±e;
Table III). A further four patients carried previously reported
mutations N171del (patients 4, 6, and 7; Bowden et al, 1995) and
F174S (patient 5; Smith et al, 1999a) in the K6a gene (Table III,
molecular data not shown). Patients 8 and 9, also diagnosed as PC-
1, were found to carry novel heterozygous mis-sense mutations in
the K16 gene, M121T and L128Q, respectively (Fig 2a±c;
Table III). Therefore, all patients diagnosed as having the PC-1
variant were found to carry mutations in the K6a or K16 genes.
A mutation detection strategy for the entire coding region of the
functional K17 gene was developed based on long-range PCR. By
this means, molecular analysis of the K17 gene was performed in
the four patients diagnosed as PC-2 on the basis of pilosebaceous
cysts (Table III). In one case, the presence of natal teeth was an
additional indicator of PC-2 (patient 12). Three novel K17
mutations were found, L95P, S97del, and L99P in patients 10±
12, respectively (Fig 3a±d; Table III). The fourth PC-2 case was
found to have a recurrent mutation in K17 (R94H), which has
previously been reported (Covello et al, 1998; Smith et al, 1997). Of
particular interest was mutation S97del detected in a sporadic case,
patient 11. This 3 bp deletion is similar to a 3 bp deletion mutation
previously identi®ed in K16 in a sporadic case of PC-1 (Smith et al,
1999b).
All novel mutations were excluded from a population of 50
ethnically matched, normal, unrelated individuals by restriction
digestion of short PCR products spanning the appropriate regions
of the K6a, K16, or K17 genes (Figs 1f±h, 2d, e, and 3e, f).
Therefore, these defects were excluded as common polymorphisms
in the human population by this standard genetic test (Cooper and
Figure 3. Novel mutations in the K17 gene.
(a) Normal DNA sequence of K17 exon 1, region
encoding the helix initiation motif. (b) DNA
sequence as shown in (a), derived from patient 12,
showing heterozygous mis-sense mutation
284T > C, predicting the amino acid change
L95P (or L11P in the 1A domain). (c) DNA
sequence as shown in (a), derived from patient 11,
showing overlapping sequence traces due to
heterozygous deletion mutation 289delCCT,
predicting the amino acid change S97del (or
S13del in the 1A domain). (d) DNA sequence as
shown in (a), derived from patient 10, showing
heterozygous mis-sense mutation 296T > C,
predicting the amino acid change L99P (or L15P
in the 1A domain). (e) Con®rmation of mutations
L95P and L99P by NciI digestion. M, molecular
weight markers. Lane 1, digest derived from
patient 10 showing digested mutant bands; lane
2, digest derived from patient 12 showing digested
mutant bands; lanes 3±8, digests derived from
normal unrelated controls. (f) Con®rmation of
mutation S97del by S®I digestion. M, molecular
weight markers. Lane 1, digest derived from
patient 11 showing digested mutant bands; lanes
2±8, digests derived from normal unrelated
controls.
Figure 2. Novel mutations in the K16 gene.
(a) Normal DNA sequence of K16 exon 1, region
encoding the helix initiation motif. (b) DNA
sequence as shown in (a), derived from patient 8,
showing heterozygous mis-sense mutation
362T > C, predicting the amino acid change
M121T (or M4T in the 1A domain). (c) DNA
sequence as shown in (a), derived from patient 9,
showing heterozygous mis-sense mutation
383T > A, predicting the amino acid change
L128Q (or L11Q in the 1A domain). (d)
Con®rmation of mutation M121T by NlaIII
digestion. M = molecular weight markers. Lanes
1, 3±8, digests derived from normal unrelated
controls; lane 2, digest derived from patient 8
showing undigested mutant band. (e)
Con®rmation of mutation L128Q by StuI
digestion. M = molecular weight markers. Lane
1, digest derived from patient 9 showing digested
mutant bands; lanes 2±8, digests derived from
normal unrelated controls.
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Krawczak, 1993). Population screening for the recurrent mutations
was performed in the original reports of these defects (Bowden et al,
1995; Covello et al, 1998; Smith et al, 1999a).
DISCUSSION
Mutation detection strategies for PC mutation
hotspots Here, we describe eight novel mutations in patients
with PC: mutations F174V, E472K, and L469R in K6a; M121T
and L128Q in K16; and L95P, S97del, and L99P in K17. In
addition, we report ®ve new occurrences of three previously
reported mutations, N171del and F174S in K6a and R94H in K17
(data not shown). All the mutations described here occur in the
helix boundary motif sequences of these keratins, located at the start
of the helix 1A domain and the end of the helix 2B domain. To
allow comparison with mutations in other keratins, the 1A and 2B
domain residue numbers are shown in Table III alongside the
codon numbers for these mutations.
Of the recurrent mutations, N171del was identi®ed in one
familial and two sporadic cases here (patients 4, 6, and 7) and
previous reports of K6a (Bowden et al, 1995). The analogous
mutation has also been reported in the K4 gene in two cases of
white sponge nevus (Rugg et al, 1995). This mutation is consistent
with DNA polymerase slippage during replication of three tandem
CAA repeats present in exon 1 of several type II keratin genes,
including K4 and K6a (Cooper and Krawczak, 1993). The novel
3 bp K17 mutation S97del reported here probably occurred
through a similar slippage mechanism, as it involves two tandem
repeats of CTT (Fig 3). Similarly, the other recurrent mutation,
R94H in K17, occurs in a CpG-containing arginine codon found
in exon 1 of most type I keratins. Deamination of CpG
dinucleotides is the most common mechanism underlying point
mutations in humans (Cooper and Krawczak, 1993). Thus,
genomic instability within the ®rst exon of the K6a and K17
genes probably explains why these are the most common mutations
reported in PC.
There are no very obvious causative mechanisms for the other
mutations reported here; however, most PC mutations reported to
date, including those here, occur in the helix boundary motif
sequences of the keratin polypeptides involved. The exceptions are
a deletion involving the V1 domain of K16 in a keratinous
palmoplantar nevus (Terrinoni et al, 2000) and a mutation in the
central 2B domain of K16 in a case of late-onset PC (Connors et al,
2001). The helix boundary motifs are mutational hotspots for all
keratin disorders characterized to date (Fuchs and Cleveland, 1998;
Irvine and McLean, 1999) and are encoded by exons 1 and 6 in
type I keratin genes and exons 1 and 7 in type II keratin genes.
Therefore, in PC like other keratin disorders, mutation analysis
should focus ®rst on these exons and only when these are excluded
is it worthwhile screening other regions of these genes. It should
also be noted that we have previously screened a few cases of PC
that do not fall into the PC-1 or PC-2 classi®cations and detected
no mutations in any of the K6a, K6b, K16, or K17 genes (Smith
and McLean, unpublished data). Therefore, there are some cases of
PC where an unknown gene or genes may be involved.
The keratin genes that are known to be involved in PC are
particularly dif®cult to analyze due to the presence of multiple
isogenes and/or pseudogenes (Troyanovsky et al, 1992; Takahashi
et al, 1995; Smith et al, 1999b). The mutation detection strategy
that we have employed here for K6a and K16 is based on long-
range PCR covering all or most of the target gene (Smith et al,
1999a, b). For the K17 gene, a speci®c long-range PCR is reported
here, allowing analysis of all exons of this gene in the future. Only
one case of a K6b mutation has been reported (Smith et al, 1998).
Collectively, these methods allow detection of most PC mutations
without coampli®cation of nonfunctional or irrelevant genes.
Diagnosis and genotype±phenotype correlation in PC Here,
we were able to classify our patients as PC-1 or PC-2 on the basis of
the clinical phenotype, as outlined in Table III. The most useful
distinguishing feature for PC-2 patients is the presence of
pilosebaceous cysts from puberty. Younger patients are more
dif®cult to classify, although very prominent oral lesions are more
typical of PC-1 and natal teeth, when present, are indicative of PC-2
(Table III). The differences in the PC-1 and PC-2 phenotypes can
be largely explained by the difference in expression patterns between
the K6a/K16 and K6b/K17 expression pairs (McGowan and
Coulombe, 2000). K6b/K17 are expressed at higher levels in the
pilosebaceous unit than K6a/K16, explaining the pilosebaceous cysts
in PC-2. Conversely, K6a/K16 are more widely expressed in oral
epithelia, explaining the greater predominance of oral leukokeratosis
in PC-1 (Table I).
In conclusion, we report keratin mutations in 13 cases of PC.
The genotype±phenotype correlation, mutation clustering data,
and long-range PCR methodology presented here should serve as
useful guidelines for improved diagnosis and molecular genetic
analysis of future cases of this group of keratinizing disorders.
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